See more : Signal Gold Inc. (SGNLF) Income Statement Analysis – Financial Results
Complete financial analysis of Bonus BioGroup Ltd. (BONS.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bonus BioGroup Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Karma Energy Limited (KARMAENG.NS) Income Statement Analysis – Financial Results
- CTS Corporation (CTS) Income Statement Analysis – Financial Results
- The Manitowoc Company, Inc. (MTW) Income Statement Analysis – Financial Results
- Termbray Industries International (Holdings) Limited (0093.HK) Income Statement Analysis – Financial Results
- Indo Thai Securities Limited (INDOTHAI.NS) Income Statement Analysis – Financial Results
Bonus BioGroup Ltd. (BONS.TA)
About Bonus BioGroup Ltd.
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.37M | 4.10M | 1.61M | 0.00 | 0.00 | 1.34M | 1.14M | 904.00K | 1.35M | 608.00K | 169.00K |
| Gross Profit | 0.00 | -3.37M | -4.10M | -1.61M | 0.00 | 0.00 | -1.34M | -1.14M | -904.00K | -1.35M | -608.00K | -169.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.61M | 21.31K | 20.79K | 11.36K | 11.08M | 10.82M | 10.89M | 8.56M | 9.37M | 9.44M | 6.08M | 0.00 |
| General & Administrative | 11.18M | 5.46M | 31.34M | 2.80M | 2.39M | 2.10M | 3.31M | 3.03M | 4.55M | 2.23M | 2.56M | 2.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.00K | 258.00K | 676.00K | 251.00K | 244.00K | 176.00K | 157.00K |
| SG&A | 11.18M | 5.46M | 31.34M | 2.80M | 2.39M | 2.10M | 3.31M | 3.03M | 4.55M | 2.23M | 2.56M | 2.64M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.24M |
| Operating Expenses | 29.82M | 33.68M | 60.64M | 17.84M | 20.91M | 18.45M | 18.79M | 14.82M | 12.49M | 9.85M | 9.14M | 8.61M |
| Cost & Expenses | 29.82M | 37.05M | 64.74M | 19.44M | 20.91M | 18.45M | 20.13M | 15.96M | 13.40M | 11.20M | 9.75M | 8.78M |
| Interest Income | 879.00 | 7.28M | 164.00K | 0.00 | 0.00 | 79.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 891.00K | 569.00K | 408.00K | 460.00K | 364.00K | 67.00K | 83.00K | 61.00K | 27.00K | 24.00K | 10.00K |
| Depreciation & Amortization | 1.65M | 2.66M | 1.48M | 1.07M | 1.08M | 197.00K | 163.00K | 410.00K | 489.00K | 459.00K | 223.00K | 4.00K |
| EBITDA | -28.14M | -35.60M | -67.05M | -18.39M | -20.03M | -18.17M | -19.97M | -15.43M | -12.91M | -10.74M | -9.53M | -18.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.79M | -37.05M | -64.74M | -19.44M | -20.91M | -18.45M | -20.13M | -15.96M | -13.40M | -11.18M | -9.68M | -17.96M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.26M | -1.66M | -25.34M | -2.58M | -1.33M | -285.00K | -67.00K | -83.00K | -61.00K | -7.00K | 48.00K | -10.00K |
| Income Before Tax | -28.53M | -38.70M | -90.08M | -22.02M | -22.24M | -18.74M | -20.20M | -16.05M | -13.46M | -11.21M | -9.70M | -17.97M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.26M | -3.79M | -15.00K | -195.00K | 79.00K | 0.00 | 119.00K | 0.00 | -20.00K | -72.00K | -56.00K |
| Net Income | -28.53M | -38.70M | -90.08M | -22.02M | -22.24M | -18.74M | -20.20M | -16.05M | -13.46M | -11.21M | -9.70M | -17.97M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.06 | -0.16 | -0.06 | -0.07 | -0.07 | -0.08 | -0.07 | -0.06 | -0.06 | -0.06 | -0.15 |
| EPS Diluted | -0.02 | -0.06 | -0.16 | -0.06 | -0.07 | -0.07 | -0.08 | -0.07 | -0.06 | -0.06 | -0.06 | -0.15 |
| Weighted Avg Shares Out | 1.17B | 621.08M | 579.12M | 393.93M | 306.25M | 283.68M | 259.56M | 233.54M | 214.40M | 201.67M | 174.46M | 120.76M |
| Weighted Avg Shares Out (Dil) | 1.17B | 621.08M | 579.12M | 393.93M | 306.25M | 283.68M | 259.56M | 233.54M | 214.40M | 201.67M | 174.46M | 120.76M |
Source: https://incomestatements.info
Category: Stock Reports